SequelSEC

ROCKWELL MEDICAL, INC. RMTI

Pharmaceutical Preparations · CIK 0001041024 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$69.39M
Fiscal year ended 2026-06-30
Operating income
-$4.52M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$28.69MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.73Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue0.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.8×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
R&D / revenue0.0%0th
Gross margin16.9%9th
SBC / revenue2.6%14th
Operating margin-6.8%76th
Revenue YoY growth-31.8%29th
Net margin-7.7%70th
Long-term debt / equity0.24x35th
Current ratio3.98x52th

ROCKWELL MEDICAL, INC. (RMTI) reported revenue of $69.39M and net income of -$5.08M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ROCKWELL MEDICAL, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ROCKWELL MEDICAL, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$69.39M
Cost of revenue$57.10M
Gross profit$12.29M
Operating income-$4.52M
Net income-$5.08M
Research & developmentUnavailable
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrative$16.77M
General & administrative$14.56M
Selling & marketing$2.22M

Balance

ROCKWELL MEDICAL, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$10.52M
Total assets$56.53M
Current assets$36.36M
Total liabilities$21.44M
Current liabilities$11.17M
Total equity incl. NCI$35.08M
Temporary (mezzanine) equityUnavailable
Inventory$2.82M
Accounts receivable$8.30M
Goodwill$920.00K
Long-term debt$7.24M
Accounts payable$3.18M

Cash flow

ROCKWELL MEDICAL, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$2.90M
Capital expendituresUnavailable
Investing cash flow-$9.05M
Financing cash flow$4.19M
Net change in cash-$1.96M
Stock-based compensation$1.87M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$2.09M

Derived

ROCKWELL MEDICAL, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross margin17.7%
Operating margin-6.5%
FCF marginUnavailable
SBC / revenue2.7%
Current ratio3.25x
Revenue YoY growth-21.1%
Net margin-7.3%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equity0.21x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RMTI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.